mRNA Vaccines for Flu

This trial tests new mRNA flu vaccines to determine their safety and effectiveness in triggering the body's immune response against the flu virus. Participants will receive one dose of either an experimental mRNA flu vaccine or a standard flu vaccine for comparison. The trial aims to identify which vaccines work best and are safe for future use. Healthy adults who haven't had the flu or a flu shot in the last five months might be suitable candidates. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group, providing an opportunity to contribute to important vaccine development.

The trial information does not specify if you need to stop taking your current medications. However, if you have taken antiviral medications for the flu in the last 5 months, you cannot participate.

Research has shown that the mRNA flu vaccines under study are generally safe. For Vaccine Candidate #1, studies found mild to moderate side effects, such as pain at the injection site, which resolved quickly. Serious side effects were rare. Vaccine Candidate #2 and Candidate #3 also demonstrated good safety, with no major concerns and mostly mild, temporary side effects.

Recent research on Vaccine Candidate #4 found no major safety issues, with some participants reporting mild reactions like soreness. Vaccine Candidate #5 and Candidate #6 also exhibited mild side effects, primarily short-lasting discomfort at the injection site. No serious problems emerged in these studies.

Researchers are excited about these mRNA flu vaccine candidates because they offer a cutting-edge approach different from traditional flu vaccines, which typically use inactivated or weakened viruses. Unlike those standard vaccines, mRNA vaccines work by instructing cells to produce a protein that triggers an immune response, potentially leading to a more robust and targeted protection against the flu. The rapid adaptability of mRNA technology also means these vaccines can be updated quickly to match circulating flu strains, offering a significant advantage in responding to seasonal changes. Additionally, because these vaccines use a synthetic process rather than growing viruses in eggs, they can be produced more rapidly and with fewer allergic reactions.

This trial will evaluate multiple mRNA influenza vaccine candidates. Research has shown that mRNA-based flu vaccines hold promise. Studies have found that these vaccines, such as mRNA-1010, can be more effective than traditional egg-based flu vaccines. In some trials, mRNA flu vaccines outperformed regular flu shots by about 26.6% to 35%. These vaccines use mRNA to train the body to combat the flu virus, resulting in strong immune responses. Early results also suggest they are generally safe, with mostly mild and short-lasting side effects. Overall, evidence supports that mRNA flu vaccines could offer better protection against the flu.¹²⁶⁷⁸